马来酸依那普利叶酸片治疗H型高血压的系统评价

杜彪; 张杰; 谢星星; 周春阳<sup>*</sup>; 杜扬

引用本文:	杜彪,张杰,谢星星,周春阳,杜扬.马来酸依那普利叶酸片治疗H型高血压的系统评价[J].中国现代应用药学,2015,32(12):1488-1493.
	DU Biao,ZHANG Jie,XIE Xingxing,ZHOU Chunyang,DU Yang.Systematic Review of Enalapril-folic Acid Tablet in Treatment of H-type Hypertension[J].Chin J Mod Appl Pharm(中国现代应用药学),2015,32(12):1488-1493.

【打印本页】【HTML】【下载PDF全文】【查看/发表评论】【EndNote】【RefMan】【BibTex】

←前一篇|后一篇→

过刊浏览高级检索

本文已被：浏览 2173次下载 1709次	码上扫一扫！
分享到：微信更多字体:加大+\|默认\|缩小-
马来酸依那普利叶酸片治疗H型高血压的系统评价
杜彪¹, 张杰², 谢星星³, 周春阳², 杜扬⁴
1.重庆三峡中心医院，重庆 404000;2.川北医学院，四川南充 637000;3.四川医科大学，四川泸州 646000;4.重庆医科大学，重庆 400016

摘要:

目的系统评价马来酸依那普利叶酸片治疗H型高血压的临床疗效和安全性。方法计算机检索CNKI、维普、万方、PubMed、Medline、EMbase和相关数据库，辅以文献追溯、网上查询等方法，检索建库至2015年5月31日国内外公开发表的马来酸依那普利叶酸片治疗H型高血压随机对照研究，采用RevMan 5.0软件进行定量综合分析。结果共纳入17篇对照研究，合计H型高血压患者2 323例。其中14项研究介绍了SBP改变情况，结果显示：WMD=-6.73，95%CI：-10.13~-3.39，Z=3.93，P<0.05；14项研究介绍了DBP改变情况，结果显示：WMD=-6.76，95%CI：-10.23~-2.51，Z=5.96，P<0.05；17项研究介绍了Hcy改变情况，结果显示：WMD=-4.18，95%CI：-6.58~-3.03，Z=5.32，P<0.05；7项研究介绍了心脑血管事件发生情况，结果显示：OR=0.28，95%CI：0.18~0.43，Z=5.96，P<0.05。常见不良反应无显著性差异。结论马来酸依那普利叶酸片治疗H型高血压的疗效和安全性优于马来酸依那普利。

关键词: 高血压马来酸依那普利马来酸依那普利叶酸片同型半胱氨酸系统评价

DOI：

分类号:

基金项目:重庆市万州区科技计划资助项目(201403055)

Systematic Review of Enalapril-folic Acid Tablet in Treatment of H-type Hypertension

DU Biao¹, ZHANG Jie², XIE Xingxing³, ZHOU Chunyang², DU Yang⁴

1.Chongqing Three Gorges Central Hospital, Chongqing 404000, China;2.North Sichuan Medical College, Nanchong 637000, China;3.Sichuan Medical University, Luzhou 646000, China;4.Chongqing Medical University, Chongqing 400016, China

Abstract:

OBJECTIVE To evaluate the clinical efficacy and safety of enalapril-folic acid in the treatment of H-type hypertension. METHODS Retrieved from CNKI, VIP, Wanfang database, PubMed, Medline and EMBase, RCTs about Enalapril-folie acid treatment of H-type hypertension were collected and evaluated by Cochrane systematic review. Meta-analysis was carried out by using RevMan 5.0 software. RESULTS The 17 studies were included, involving 2 323 patients. Meta-analysis showed that there was statistical significant between enalapril-folic acid and enalapril on SBP(WMD=-6.73, 95%CI: -10.13- -3.39, Z=3.93, P<0.05), DBP(WMD=-6.76, 95%CI: -10.23- -2.51, Z=5.96, P<0.05) and Hcy(WMD=-4.18, 95%CI: -6.58- -3.03, Z=5.32, P<0.05). The incidence of cardiovascular events in both group had significant difference (OR=0.28, 95%CI: 0.18-0.43, Z=5.96, P<0.05) and the common adverse reactions had no significant difference. CONCLUSION Enalapril-folic acid is more effective and safety than enalapril for treatment of H-type hypertension.

Key words: hypertension enalapril enalapril-folic acid tablet homocysteine systematic review